KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Astrazeneca (AZN) Gross Margin (2016 - 2025)

Historic Gross Margin for Astrazeneca (AZN) over the last 16 years, with Q4 2025 value amounting to 79.89%.

  • Astrazeneca's Gross Margin fell 18100.0% to 79.89% in Q4 2025 from the same period last year, while for Dec 2025 it was 81.9%, marking a year-over-year increase of 7700.0%. This contributed to the annual value of 81.9% for FY2025, which is 7700.0% up from last year.
  • As of Q4 2025, Astrazeneca's Gross Margin stood at 79.89%, which was down 18100.0% from 81.56% recorded in Q3 2025.
  • In the past 5 years, Astrazeneca's Gross Margin registered a high of 5257.59% during Q4 2022, and its lowest value of 61.49% during Q4 2021.
  • For the 5-year period, Astrazeneca's Gross Margin averaged around 706.48%, with its median value being 81.74% (2023).
  • Its Gross Margin has fluctuated over the past 5 years, first skyrocketed by 51961000bps in 2022, then plummeted by -51767900bps in 2023.
  • Over the past 5 years, Astrazeneca's Gross Margin (Quarter) stood at 61.49% in 2021, then skyrocketed by 8450bps to 5257.59% in 2022, then tumbled by -98bps to 80.81% in 2023, then grew by 1bps to 81.7% in 2024, then decreased by -2bps to 79.89% in 2025.
  • Its Gross Margin stands at 79.89% for Q4 2025, versus 81.56% for Q3 2025 and 82.89% for Q2 2025.